{"id":"NCT00931632","sponsor":"Mallinckrodt","briefTitle":"Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants","officialTitle":"Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2013-05","completion":"2014-05","firstPosted":"2009-07-02","resultsPosted":"2015-08-11","lastUpdate":"2017-12-04"},"enrollment":451,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bronchopulmonary Dysplasia"],"interventions":[{"type":"DRUG","name":"Inhaled Nitric Oxide","otherNames":["INOmax"]},{"type":"DRUG","name":"Placebo","otherNames":["Nitrogen gas"]}],"arms":[{"label":"Inhaled Nitric Oxide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This phase 3, multi-center, double blind, placebo-controlled, randomized clinical trial will attempt to demonstrate if preterm infants who require mechanical ventilation and/or positive pressure support at any point during days 5 to 14 after birth may benefit from treatment with iNO.","primaryOutcome":{"measure":"Survival Without BPD at 36 Weeks","timeFrame":"Baseline, 36 weeks PMA","effectByArm":[{"arm":"Inhaled Nitric Oxide","deltaMin":80,"sd":null},{"arm":"Placebo","deltaMin":70,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.427"}]},"eligibility":{"minAge":"5 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":33,"countries":["United States","Canada"]},"refs":{"pmids":["28973344"],"seeAlso":["http://jamanetwork.com/journals/jamapediatrics/article-abstract/2654598"]},"adverseEventsSummary":{"seriousAny":{"events":105,"n":229},"commonTop":["Hyponatraemia","Metabolic acidosis","Bronchopulmonary dysplasia","Pulmonary edema","Feeding disorder neonatal"]}}